A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate

- At least three core biopsies positive for prostate cancer (a minimum of 6 core
biopsies must be obtained at baseline). A prostate biopsy within 6 months from
Screening is allowed for entry requirements

- At least one of the following features: prostate specific antigen (PSA) greater than
(>) 10 nanogram per milliliter (ng/ml); PSA velocity >2 ng/ml per /year (defined as a
rise in PSA of >2 ng/ml in the preceding 12 month period); Gleason score greater than
or equal to (>=) 7 (4+3); Gleason score 6 if either PSA >=10 ng/ml or PSA velocity
>=2 ng/ml/year

- Serum testosterone >200 nanogram/deciliter

- Participant and urologist must agree that participant is suitable for prostatectomy

Exclusion Criteria:

- Serious or uncontrolled co-existent, non-malignant disease, including active and
uncontrolled infection

- Abnormal liver function consisting of any of the following: serum bilirubin >= 1.5 *
upper limit of normal (ULN); aspartate aminotransferase or alanine aminotransferase
>=2.5 * ULN

- Uncontrolled hypertension within the Screening period (systolic blood pressure
>= 160 millimeter of mercury [mmHg] or diastolic BP >= 95 mmHg)

- Requirement for corticosteroids greater than the equivalent of 5 milligram of
prednisone daily

- Participants with active or symptomatic viral hepatitis or chronic liver disease or
clinically significant heart disease or as evidenced by myocardial infarction,
or arterial thrombotic events in the past 6 months, severe or unstable
angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac
ejection fraction measurement of < 50 percent at Baseline or history of
gastrointestinal disorders (medical disorders or extensive surgery) which may
interfere with the absorption of the study drug or history of pituitary or adrenal
dysfunction